RxDoctor Payments Data

Dean Monson, APRN

Family · St George, UTNPI 1558796391

Payments from drug & device makers

$505in general payments, 2019–2025

Across 15 payments — averaging $33.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$167
  • Braeburn Inc.$141
  • Johnson & Johnson$55
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$47
  • E.r. Squibb & Sons, L.L.C.$40
  • Pharmacyclics LLC, An Abbvie Company$24
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$45891%
  • Education$479%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$505 in reported general payments places this provider in the 55th percentile of 1,460 family providers in Utah.

See all family providers in Utah

Medicare billing

Part B allowed, 2024
$7,801
Medicare patients
15
Services billed
82

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate20$147,383
Invega TrinzaPaliperidone Palmitate12$106,019
AristadaAripiprazole Lauroxil27$65,407
VraylarCariprazine Hcl37$55,511
CaplytaLumateperone Tosylate23$37,472
Invega SustennaPaliperidone Palmitate11$26,829
Paliperidone ErPaliperidone14$5,423
Clozapine52$3,729
Aripiprazole28$1,130
Trazodone Hcl103$1,105
Haloperidol Decanoate15$1,078
Duloxetine Hcl48$1,069
Risperidone60$901
Benztropine Mesylate58$806
Naltrexone Hcl21$759

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna$55$132,84823 claims
Alkermes, Inc.Aristada$17$65,40727 claims
AbbVieVraylar$167$55,51137 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$47$37,47223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,460 family providers in Utah.

Other family in St George

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →